Can-Fite BioPharma American Depositary Shares
CANF
14 hedge funds and large institutions have $198K invested in Can-Fite BioPharma American Depositary Shares in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 4 closing their positions.
46% more capital inflows, than outflows
Capital inflows: $83.4K | Capital outflows: $57.2K
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
8% more funds holding
Funds holding: 13 → 14 (+1)
0.28% more ownership
Funds ownership: 1.92% → 2.2% (+0.28%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XTX Topco
George Town,
Cayman Islands
|
+$24.4K |
| 2 |
Virtu Financial
New York
|
+$21.9K |
| 3 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$18.1K |
| 4 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$17K |
| 5 |
Costello Asset Management
Feasterville,
Pennsylvania
|
+$1.59K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Securities
New York
|
-$31.5K |
| 2 |
Morgan Stanley
New York
|
-$14.8K |
| 3 |
Kohmann Bosshard Financial Services
Fairlawn,
Ohio
|
-$5.53K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$4.14K |
| 5 |
Citigroup
New York
|
-$899 |
CANF Hedge Fund Activity: Q1 2025 in Review
14 of the 7,484 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q1 2025, worth a combined $198K — up 4% from $190K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CANF positions and 4 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was XTX Topco, opening a new position worth an estimated $24.4K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $31.5K sold.
- 14 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q1 2025, up from 13 in Q4 2024.
- Funds reported $198K of Can-Fite BioPharma American Depositary Shares stock for Q1 2025, up 4% quarter-over-quarter.
- 5 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q1 2025 and 4 closed out, a net change of +1 holder.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q1 2025 was XTX Topco, an estimated $24.4K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q1 2025 was Two Sigma Securities, an estimated $31.5K sold.
Based on aggregated 13F filings for Q1 2025.